Home » Topics » BioWorld Science, Immune

BioWorld Science, Immune
RSS

La Jolla presents new Toleragen compound with potential to treat autoimmune blood clotting disorder

May 14, 1999

Licensing opportunity from Stanford University: treatment of autoimmune disorders

May 13, 1999

NIAID seeks authorization to begin first clinical trials of GAS vaccine in over 20 years

May 12, 1999

Lyme disease vaccine technology available for licensing from Brookhaven National Laboratory

May 12, 1999

Proinflammatory effects demonstrated for SDZ-RAD in rat model of glomerulonephritis

May 11, 1999

KH-1060: immunomodulating effects studied in mouse skin graft model

May 10, 1999

Naturally occurring terpene with immunosuppressive and neovascularization-inhibitory effects

May 10, 1999

Phase I trial with Ariad's first Dimerizer Drug successfully completed

May 7, 1999

U.K. regulatory filing for Wyeth Lederle Vaccines' meningococcal C conjugate vaccine

May 7, 1999

Idec describes preparation, pharmacology and use of humanized anti-gp39 MAbs

May 6, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Other news to note for July 22, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
GSK’s newly acquired Jideytro wins FDA nod in NSCLC
BioWorld
About a week after closing its $10.6 billion acquisition of Nuvalent Inc., GSK plc has reaped the first reward, announcing U.S. FDA approval of zidesamtinib in...